EMA Recommends Granting a Marketing Authorisation for Vimseltinib By Ogkologos - September 5, 2025 273 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adults with symptomatic tenosynovial giant cell tumour Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Cancer in children and young people: how far we’ve come September 29, 2021 Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... June 23, 2023 On Giving Tuesday, You Helped Us Raise $334,449 For People, Pets,... December 13, 2019 Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described June 25, 2021 Load more HOT NEWS Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours Progress in Treating Liver Cancer and Biliary Tract Cancer with Immunotherapy:... Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of... Delayed irAEs Occur in a Small Subset of Patients with Melanoma,...
